

Q2 2022 *results*

sanofi



• Our performance in the second quarter was once again fueled by both higher sales across our key growth drivers and outstanding financial results. We remain ahead of schedule on our strategy and are confident in the outlook for the second half of the year. •

Paul Hudson

Chief Executive Officer

Company sales and business EPS*

€10,116m

+8.1 % (+15.7 %)

Q2 2022
company sales**



€1.73

+16.7 % (+25.4 %)

Q2 2022
business EPS**

* Earnings per share

** Growth rates are expressed at constant exchange rates (CER).
Growth rates in parentheses are expressed on a reported basis.

Sales by global business unit




€4,076m

Specialty Care



€3,597m

General Medicines



€1,178m

Vaccines



€1,265m

Consumer Healthcare

Sales by geography

US

€4,078m

Europe

€2,375m



Rest of
the World

€3,663m

Research & Development achievements



Rare
diseases

Approval in Europe of two new treatments for:
- Pompe disease
- Acid sphingomyelinase deficiency (ASMD)



Auto-immune
diseases

Progress of our biologic treatment for type 2
inflammatory diseases in two new indications in the US:
- Approval in eosinophilic esophagitis
- Priority review in prurigo nodularis



Hemophilia

New data demonstrating transformative potential
of two innovative priority assets in hemophilia A

For further information on Q2 2022 results and definitions of financial indicators, please refer to the press release issued on July 28, 2022 at:
www.sanofi.com/en/investors

sanofi



@Sanofi



@Sanofi



@Sanofi



@SanofiaventisTVen